This issue highlights the use of continuous glucose monitoring (CGM) systems, sodiumglucose transport protein-2 (SGLT2) inhibitors, newer insulin formulations, and the expert guideline recommendations focused on individualization of therapy.
In 2017, the Centers for Disease Control reported that over 30 million people in the US (~10% of the population) have diabetes, including 7.2 million who are undiagnosed. The total estimated cost of diagnosed diabetes in the US was $327 billion in 2017.2 Individuals with diabetes incur average annual medical expenses of about $16,750 – more than twice the expense for people without diabetes.
Over the last decade, the options for managing diabetes have grown dramatically – including new medication classes (eg, glucagon- like peptide-1 agonists, sodium-glucose transport protein-2 inhibitors), new insulin analogs (eg, insulin degludec, biosimilar insulins), and new technologies to help patients monitor their diabetes (eg, continuous glucose monitoring).
Clinical practice guidelines have increased the emphasis on individualizing treatment options and goals to meet the needs of each patient. Patients have more say in the management of their diabetes and overall health. It is essential that healthcare providers help patients navigate the vast pool of information available at their fingertips. Diabetes patients can easily get confused by the often-conflicting information or misinformation available on television and the internet, and from friends and family members. Community providers need a good, working knowledge of patient-specific diabetes management, including current treatments and technologies...
- This accredited program is targeted to pharmacy technicians.
This CE activity was developed by The Rx Consultant, a publication of Continuing Education Network, Inc.
CE activities for Pharmacists and Pharmacy Technicians:
This continuing education (CE) activity meets the requirements of all state boards of pharmacy for approved continuing education hours. CE credit is automatically reported to CPE Monitor.
CE activities for Nurse Practitioners and Clinical Nurse Specialists:
This continuing education activity meets the requirements of:
The American Nurses Credentialing Center (ANCC) for formally approved continuing education (CE) hours, and CE hours of pharmacotherapeutics.
The American Academy of Nurse Practitioners Certification Program (AANPCP) for acceptable, accredited CE.
This is a pharmacotherapeutics/pharmacology CE activity.
Continuing Education Network, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Requirements for CE Credit
- List the usual components of continuous glucose monitoring (CGM) devices and provide the names of 4 different types of CGM devices. List medications that may affect CGM device readings.
- List the brand and generic names of sodium-glucose cotransporter-2 (SGLT2) inhibitors. List 3 potentially serious side effects of this class of medications.
- For the newer insulin analogs, list the generic and brand names, and the insulin analogs available as "biosimilars." State which insulin analogs are available as a pen formulation as well as a 10 mL multidose vial.
Amanda Stahnke, PharmD, BCACP
Brief Bio : Amanda Stahnke, PharmD, BCACP is a Clinical Assistant Professor in the Department of Pharmacy Practice and Administration at the University of Missouri-Kansas City School of Pharmacy. She serves as a Patient-Aligned Care Team (PACT) Pharmacist at the Kansas City Veterans Affairs Medical Center.
Andrew Bzowyckyj, PharmD BCPS, CDE
Brief Bio : Andrew Bzowyckyj, PharmD BCPS, CDE is an Associate Professor in the School of Pharmacy at Pacific University Oregon in Hillsboro, Oregon.